New combo therapy aims to shrink breast tumors before surgery
NCT ID NCT06650748
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the targeted drug dalpiciclib to standard hormone therapy (letrozole) before surgery can improve outcomes for women with HR+/HER2- early-stage breast cancer. The study enrolls 100 women aged 18-70 whose tumors have a high genetic risk score and show a poor early response to hormone therapy. The goal is to see if this combination leads to a complete or near-complete disappearance of the tumor by the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dalpiciclib (a CDK4/6 inhibitor) and letrozole (an aromatase inhibitor)
What this could lead to
If successful, this could lead to a more personalized treatment approach for early-stage breast cancer, potentially improving response rates before surgery.
What could go wrong
This is a small, early-phase trial (100 participants) at a single center, so results may not apply broadly. Side effects from the drug combination, such as low blood cell counts or fatigue, are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China